Evogene (NASDAQ: EVGN) and CVR Partners (NYSE:UAN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.
This is a summary of current recommendations for Evogene and CVR Partners, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CVR Partners has a consensus price target of $5.00, indicating a potential upside of 51.52%. Given CVR Partners’ higher probable upside, analysts clearly believe CVR Partners is more favorable than Evogene.
Earnings and Valuation
This table compares Evogene and CVR Partners’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Evogene||$3.38 million||21.79||-$20.83 million||N/A||N/A|
|CVR Partners||$330.80 million||1.13||-$72.78 million||($0.64)||-5.16|
Evogene has higher earnings, but lower revenue than CVR Partners.
Volatility & Risk
Evogene has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, CVR Partners has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
This table compares Evogene and CVR Partners’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
35.7% of Evogene shares are held by institutional investors. Comparatively, 32.5% of CVR Partners shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
CVR Partners beats Evogene on 7 of the 10 factors compared between the two stocks.
Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States, Germany, and internationally. It operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides comprising microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, Dow Chemical, Syngenta, and Insolo Agroindustrial S.A. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
About CVR Partners
CVR Partners, LP produces, distributes, and markets nitrogen fertilizer products in the United States. It offers ammonia products for agricultural and industrial customers; and urea ammonium nitrate products to agricultural customers, as well as retailers and distributors. CVR GP, LLC serves as the general partner of the company. The company was founded in 2007 and is based in Sugar Land, Texas.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.